U.S. Airlines Stock News

If you are holding Acadia Healthcare Company (ACHC) stock, or thinking about getting in, this week’s news probably caught your eye. The company is now under investigation by the U.S. Attorney’s Office after being served a grand jury subpoena, specifically targeting its admissions, length of stay, and billing practices. In addition, Acadia faces a securities class action lawsuit that claims it withheld key information, and management just cut their full-year outlook for both revenue and...

AMFI (OTCPK:AFIP.A) may not always grab headlines, but its recent moves in the market have investors wondering what the next chapter might hold. There’s no major headline event or explosive news to explain recent activity, and that in itself brings an intriguing question: is the current share price momentum sending a subtle signal, or is it simply business as usual for a company flying under the radar? Looking at the past few months, AMFI’s share price hasn’t budged—flat over the past week...

If you have been watching Snowflake’s stock lately, you know the feeling: should you jump in, hold tight, or take some gains after its nearly 99% surge over the past year? The data cloud company is a favorite talking point among both bullish tech investors and cautious analysts, and recent price moves have certainly kept everyone on their toes. Just in the past month, Snowflake’s share price has climbed another 13.6%, contributing to a striking 41.9% gain year-to-date. While three-year...

In recent days, Teradyne attracted heightened investor attention following an analyst upgrade that cited strong demand and a deepening partnership with Taiwan Semiconductor Manufacturing Company (TSMC) for advanced semiconductor testing technologies. This collaboration highlights Teradyne’s growing position in the AI and GPU wafer sort testing market, reinforcing its role in the evolving artificial intelligence supply chain. We’ll examine how Teradyne’s increasing collaboration with TSMC for...

In the past year, Texas Roadhouse expanded its dining locations at an average annual rate of 6.1% and achieved 7.5% year-over-year growth in same-store sales, highlighting robust operational performance. This growth has been paired with an average five-year return on invested capital of 20.7%, illustrating effective capital management and profitable expansion for the company. We'll explore how Texas Roadhouse's strong same-store sales momentum shapes its updated investment narrative. The end...

Earlier this week, Nexstar Media Group removed Jimmy Kimmel's late-night show from its 33 affiliate stations following controversy over Kimmel's comments about the shooting death of Charlie Kirk, acting under regulatory pressure as the company pursues FCC approval for its acquisition of Tegna Inc. This decision highlights how large media companies may adjust programming during sensitive merger phases, especially when regulatory scrutiny and political sensitivities are heightened. We'll...

Earlier this month, Estée Lauder Companies launched ARAMIS Intuition, its latest men's fragrance, during New York Fashion Week, featuring global ambassador Dwyane Wade and an interactive public event on the High Line, as well as a consumer-focused grooming discussion at Bloomingdale's. The company also announced that René Lammers, Ph.D., will join as Chief Research & Innovation Officer in October 2025, underscoring a broader commitment to science-driven product innovation and digital...

If you are watching Richtech Robotics (NasdaqCM:RR), this might be one of those inflection points investors love to debate. The latest catalyst, a $4 million sales agreement with Beijing Tongchuang Technology Development Co., Ltd., is expected to provide a revenue boost for the fourth quarter and a stream of recurring income. Adding to the momentum, Richtech Robotics has just been included in the S&P Global BMI Index, a move that often helps to increase visibility and fund flows from...

On September 23, 2025, Scholar Rock announced that the U.S. FDA issued a Complete Response Letter for the apitegromab Biologics License Application due to manufacturing issues identified at Catalent Indiana, a third-party fill-finish facility. Importantly, the FDA's feedback relates exclusively to facility observations and does not involve any concerns regarding the drug's clinical data or patient safety. We'll examine how this regulatory delay, rooted in third-party manufacturing concerns,...

ADMA Biologics (ADMA) just caught the market’s attention with its inclusion in the Renaissance Investment Management Small Cap Growth Strategy portfolio, signaling that some investors are seeing something to get excited about. The timing seems right: demand for the company’s main drug, Asceniv, is running ahead of what the company can supply, and planned revenue milestones look ambitious. With little threat from generics to its core offerings and profitability trends heading in the right...

In the second quarter of 2025, Futu Holdings reported a very large sequential increase in operating margin and a 70% year-over-year rise in revenues, driven by growth in funded accounts, expanding overseas client penetration, and high client retention. Management highlighted strong confidence in hitting their annual target of 800,000 new funded accounts, emphasizing the impact of AI and automation investments on operating efficiency and future growth potential. We will assess how these...

On September 15, 2025, STAG Industrial, Inc. finalized a series of amendments and extensions to several key unsecured term loans and its US$1.0 billion credit facility, extending maturities and altering interest rate calculation methods for improved financial flexibility. A unique aspect of these amendments was the removal of the 0.10% SOFR adjustment and a fixed-rate interest swap on a major US$300 million loan, emphasizing the company's proactive efforts to optimize its debt profile amid...

If you have Powell Industries (NasdaqGS:POWL) on your watchlist, you might be wondering whether now is an opportune moment to act. The company has drawn significant attention for posting a 34% return on capital employed, which is far above the electrical industry average. With revenue growing and internal reinvestment paying off, Powell’s standout performance among small-cap names has prompted investors to reconsider whether the stock’s strengths could outweigh certain risks, such as its...

If you are deciding what to do with your GE HealthCare Technologies stock, or thinking about buying in, you are definitely not alone. With shares closing at $74.60, investors have seen the stock dip by 3.7% over the past week, slip 0.8% in the past month, and decline 4.8% since the beginning of the year. Over the last 12 months, shares are down 19.0%. That kind of pullback can either make you cautious or, if you are looking for bargains, very interested. Some of the recent pressure on the...

If you are watching Floor & Decor Holdings (FND) right now, you are probably wondering if this is the turning point investors have been waiting for. Over the past week, the company has celebrated the grand opening of its new warehouse-format store in Antelope Valley, adding to its footprint of over 250 locations. This comes at a moment when analysts are buzzing about the potential upside for home improvement stocks, thanks to signals that lower borrowing costs could spur a new wave of...

Evergy's Strategic Move: Exploring Advanced Nuclear with TerraPower Evergy (EVRG) just made headlines by partnering with TerraPower and the Kansas Department of Commerce, signing a memorandum of understanding to explore building a pioneering Natrium reactor and energy storage system in Kansas. This step does not guarantee a new plant, but it signals Evergy’s interest in advanced nuclear technologies that could help shape its long-term energy mix, jumpstart innovation, and even influence...

Wondering what to do with UiPath stock right now? You are not alone. There is a lot of chatter from investors weighing whether it is time to jump in or wait longer, and with such dramatic market moves recently, it makes sense to take a closer look. Over the past seven days, UiPath surged 8.3%, building on a strong 12.2% climb over the last month. Despite these short-term gains, the year-to-date number still sits at -3.1%. That might seem disappointing, but the recent momentum hints that risk...

In recent days, Crocs has faced analyst downgrades and renewed investor concerns amid rising tariff pressures and indications of weaker consumer demand for its core product lines. Analyst commentary also highlights increased competition and shifting fashion trends that could challenge Crocs’ ability to maintain sales momentum and profitability going forward. We’ll examine what heightened tariff impacts and shifting consumer preferences might mean for Crocs’ long-term investment...

US Foods Holding has caught investor attention after unveiling its Fall 2025 Scoop lineup, a collection of menu-ready products built for operators looking to streamline operations and grow margins. With operators across the industry facing pressure to manage food costs and drive profitability, these new, versatile offerings land at just the right time. The Scoop release, combined with the company’s recent reaffirmation of its 2025 growth guidance, underscores a strategic push toward...

SBA Communications (SBAC) has definitely sparked some interest lately, even if there’s no headline-grabbing event lighting up the news feed. Sometimes, the most intriguing opportunities show up when a stock quietly drifts, and it leaves investors wondering if the market knows something they don’t. After all, when the story isn’t being told for you, it’s up to us to look at the numbers and make sense of the narrative. Zooming out, the past year for SBA Communications has been mostly a test of...

Guardant Health's consensus analyst price target saw only a slight increase in the most recent update, moving from $61.33 to $62.41. This relatively stable price expectation reflects strong revenue momentum and continued leadership in liquid biopsy technology. It also shows tempered optimism following recent clinical data results. Read on to discover what is driving these perspectives and how you can stay informed about evolving developments for Guardant Health moving forward. What Wall...

If you’re looking for answers about what to do with Acadian Asset Management stock, you’re not alone. Over the past five years, this name has rocketed an impressive 279.1%, handing out growth most investors could only dream of. Even so, the ride hasn’t all been up and to the right. Just this month, shares dipped by 1.1%, and in the last week, they inched down another 0.1%. But when you zoom out, Acadian’s longer-term momentum is truly eye-catching, with an 87.8% return year-to-date. What’s...

Recent analysis indicates that CF Industries Holdings has experienced significant price swings, with assessments pointing to its current stock price being near its intrinsic value and highlighting expectations for highly negative earnings growth in coming years. This outlook has raised risk sensitivity among investors, as the combination of limited upside potential and rising earnings risks supports a more cautious approach to the company's future prospects. We'll explore how increasing...

Avadel Pharmaceuticals recently saw its consensus analyst price target edge up slightly from $20.20 to $20.30, reflecting a largely steady outlook. This minimal change is rooted in a balance between optimism over Lumryz’s commercial momentum and lingering concerns about ongoing competition in the sleep disorder market. Read on to discover how you can stay informed about ongoing shifts in the stock's narrative as new developments unfold. What Wall Street Has Been Saying Analyst commentary on...